Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the ...

GAINESVILLE, Fla., January 20, 2026--neuropacs™ Corp., a leading innovator in AI-driven neurological diagnostics, announced today the successful raise of over $1.0 million in early-stage capital.

Women neurologists of various subspecialties and career stages gathered for the 4th Annual Women in Neurology Conference, hosted by the Women Neurologists Group.

Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected ...

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S.